Cambium Bio
Clinical-stage regenerative medicine company developing biologic therapies for ophthalmology and tissue regeneration. Uses human platelet lysate and mesenchymal stem cell-based platforms to advance a pipeline that includes a topical platelet-derived ophthalmic candidate for dry eye disease and cell/secretome programs for osteoarthritis and wound healing. Publicly listed with active clinical and regulatory programs.
Industries
N/A
Products
Elate Ocular
Topical ophthalmic biologic derived from human platelet material being developed to treat dry eye disease; advanced to late clinical stages with regulatory interactions for Phase 3.
Progenza
Therapeutic program based on mesenchymal stem cells and secretome intended for intra-articular use in knee osteoarthritis; previously studied in early clinical trials.
Sygenus
Secretome-based therapeutic program in preclinical development for wound healing indications.
Elate Ocular
Topical ophthalmic biologic derived from human platelet material being developed to treat dry eye disease; advanced to late clinical stages with regulatory interactions for Phase 3.
Progenza
Therapeutic program based on mesenchymal stem cells and secretome intended for intra-articular use in knee osteoarthritis; previously studied in early clinical trials.
Sygenus
Secretome-based therapeutic program in preclinical development for wound healing indications.
Expertise Areas
- Regenerative medicine
- Ophthalmology therapeutics
- Cell therapy development
- Clinical trial management
Key Technologies
- Human platelet lysate (HPL)
- Mesenchymal stem cell (MSC) therapies
- Cell secretome-based therapeutics
- Potency and bioassay development